Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00715182 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer
A Phase 1 study of Advanced/ Metastatic Renal Cell Cancer, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 12
- Study locations
NCT00715182: Completed Phase 1 study of Advanced/ Metastatic Renal Cell Cancer, sponsored by Novartis Pharmaceuticals.
NCT00715182 is a Phase 1 study of Advanced/ Metastatic Renal Cell Cancer that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 87 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00715182, a Phase 1 study of Advanced/ Metastatic Renal Cell Cancer, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is a phase I/II open-label study to delineate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of TKI258. The eligible subject population consists of subjects who have been diagnosed with advanced or metastatic renal cell cancer that is refractory to standard therapy or for which no curative standard therapy exists.
Conditions Studied
Interventions
- DRUG TKI258
Study Locations (12)
Other
- Novartis Investigative Site - Bordeaux
- Novartis Investigative Site - Villejuif
- Novartis Investigative Site - Hanover
- Novartis Investigative Site - München
- Novartis Investigative Site - Rotterdam
- Novartis Investigative Site - Madrid
- Novartis Investigative Site - Taichung
- Novartis Investigative Site - Taipei
California
- Novartis Investigative Site - San Francisco
North Carolina
- Novartis Investigative Site - Durham
Washington
- Novartis Investigative Site - Seattle
Taiwan, ROC
- Novartis Investigative Site - Taipei
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2008-07 |
| Est. Completion | 2012-07 |
| Phase | Phase 1 |
What the finished NCT00715182 record still lists
NCT00715182 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher).
The record links to 1 condition, with Advanced/ Metastatic Renal Cell Cancer appearing as the primary indexed condition, and to 1 intervention - of which TKI258 is the first listed.
NCT00715182 lists 12 locations in 5 states (Other, California, North Carolina).
Frequently Asked Questions
What is clinical trial NCT00715182 about?
NCT00715182 is a clinical study titled "A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer". This is a phase I/II open-label study to delineate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of TKI258. The eligible subject population consists of subjects who have been diagnosed with advanced or metastatic renal cell cancer that is refractory to standard therapy or for...
What is the current status of trial NCT00715182?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2008-07. Estimated completion is 2012-07.
What conditions does trial NCT00715182 study?
This clinical trial studies the following conditions: Advanced/ Metastatic Renal Cell Cancer.
What interventions are being tested in trial NCT00715182?
The interventions under investigation include: TKI258 (DRUG).
Who is sponsoring clinical trial NCT00715182?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00715182 being conducted?
This trial has 12 study locations across California, North Carolina, Washington, Taiwan, ROC. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00715182's enrollment target sits among peer trials
87 651st of 2000 higher than 1,349 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia